CN102695510A - 囊性纤维化跨膜传导调节蛋白的嘧啶并-吡咯并-喹喔啉二酮抑制剂及其用途 - Google Patents

囊性纤维化跨膜传导调节蛋白的嘧啶并-吡咯并-喹喔啉二酮抑制剂及其用途 Download PDF

Info

Publication number
CN102695510A
CN102695510A CN2010800427350A CN201080042735A CN102695510A CN 102695510 A CN102695510 A CN 102695510A CN 2010800427350 A CN2010800427350 A CN 2010800427350A CN 201080042735 A CN201080042735 A CN 201080042735A CN 102695510 A CN102695510 A CN 102695510A
Authority
CN
China
Prior art keywords
pyrimido
dione
quinoxaline
dihydro
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800427350A
Other languages
English (en)
Chinese (zh)
Inventor
艾伦·S·韦克曼
鲁克曼尼·特拉特兰迪普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN102695510A publication Critical patent/CN102695510A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2010800427350A 2009-08-10 2010-08-10 囊性纤维化跨膜传导调节蛋白的嘧啶并-吡咯并-喹喔啉二酮抑制剂及其用途 Pending CN102695510A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23274109P 2009-08-10 2009-08-10
US61/232,741 2009-08-10
PCT/US2010/045052 WO2011019737A1 (en) 2009-08-10 2010-08-10 Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor

Publications (1)

Publication Number Publication Date
CN102695510A true CN102695510A (zh) 2012-09-26

Family

ID=43586433

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800427350A Pending CN102695510A (zh) 2009-08-10 2010-08-10 囊性纤维化跨膜传导调节蛋白的嘧啶并-吡咯并-喹喔啉二酮抑制剂及其用途

Country Status (6)

Country Link
US (1) US8609661B2 (https=)
EP (1) EP2464354B1 (https=)
CN (1) CN102695510A (https=)
CA (1) CA2769847C (https=)
IN (1) IN2012DN00719A (https=)
WO (1) WO2011019737A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105008370A (zh) * 2012-12-19 2015-10-28 诺华股份有限公司 作为cftr抑制剂的三环化合物
CN105143230A (zh) * 2012-12-19 2015-12-09 诺华股份有限公司 用于抑制cftr通道的三环化合物
CN113727711A (zh) * 2019-04-24 2021-11-30 加拉帕戈斯股份有限公司 用于治疗肾脏疾病的新化合物及其药物组合物
CN115998763A (zh) * 2023-01-17 2023-04-25 暨南大学 氯离子及靶向氯离子通道的化合物在调控铁死亡中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166658A1 (en) * 2011-05-27 2012-12-06 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
CN114948966B (zh) * 2022-04-27 2023-06-20 南京鼓楼医院 一种小分子抑制剂在制备治疗多发性硬化和脓毒症的药物中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005642A1 (fr) * 1996-08-01 1998-02-12 Centre National De La Recherche Scientifique Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
CN1246119A (zh) * 1996-12-21 2000-03-01 英国阿斯特拉药品有限公司 吡咯并[3,4－d]－嘧啶酮衍生物及其作为药物的用途
WO2004111014A1 (en) * 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
WO2005039589A2 (fr) * 2003-10-23 2005-05-06 Universite Joseph Fourier Modulateurs des canaux cftr
US20060160815A1 (en) * 2004-12-20 2006-07-20 Wyeth Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents
US20080269206A1 (en) * 2007-04-02 2008-10-30 Institute For Oneworld Health Cftr inhibitor compounds and uses thereof
WO2009076593A1 (en) * 2007-12-13 2009-06-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
EP1740532A4 (en) 2004-03-30 2009-06-10 Univ California CFTR INHIBITOR COMPOUNDS CONTAINING HYDRAZIDS AND USES THEREOF
AU2009228307A1 (en) 2008-03-25 2009-10-01 The Regents Of The University Of California Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
WO2009146144A2 (en) 2008-04-04 2009-12-03 The Regents Of The University Of California Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator
WO2012166658A1 (en) 2011-05-27 2012-12-06 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005642A1 (fr) * 1996-08-01 1998-02-12 Centre National De La Recherche Scientifique Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
CN1246119A (zh) * 1996-12-21 2000-03-01 英国阿斯特拉药品有限公司 吡咯并[3,4－d]－嘧啶酮衍生物及其作为药物的用途
WO2004111014A1 (en) * 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
WO2005039589A2 (fr) * 2003-10-23 2005-05-06 Universite Joseph Fourier Modulateurs des canaux cftr
US20060160815A1 (en) * 2004-12-20 2006-07-20 Wyeth Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents
US20080269206A1 (en) * 2007-04-02 2008-10-30 Institute For Oneworld Health Cftr inhibitor compounds and uses thereof
WO2009076593A1 (en) * 2007-12-13 2009-06-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105008370A (zh) * 2012-12-19 2015-10-28 诺华股份有限公司 作为cftr抑制剂的三环化合物
CN105143230A (zh) * 2012-12-19 2015-12-09 诺华股份有限公司 用于抑制cftr通道的三环化合物
CN105143230B (zh) * 2012-12-19 2017-06-09 诺华股份有限公司 用于抑制cftr通道的三环化合物
CN105008370B (zh) * 2012-12-19 2017-06-09 诺华股份有限公司 作为cftr抑制剂的三环化合物
CN113727711A (zh) * 2019-04-24 2021-11-30 加拉帕戈斯股份有限公司 用于治疗肾脏疾病的新化合物及其药物组合物
CN115998763A (zh) * 2023-01-17 2023-04-25 暨南大学 氯离子及靶向氯离子通道的化合物在调控铁死亡中的应用

Also Published As

Publication number Publication date
IN2012DN00719A (https=) 2015-06-19
CA2769847C (en) 2019-01-08
US20120208822A1 (en) 2012-08-16
WO2011019737A1 (en) 2011-02-17
EP2464354B1 (en) 2015-04-01
EP2464354A4 (en) 2013-03-27
US8609661B2 (en) 2013-12-17
EP2464354A1 (en) 2012-06-20
CA2769847A1 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
KR101600634B1 (ko) 항암제
US20240067600A1 (en) SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP)
TWI423977B (zh) 作為ｈｍ７４ａ同效劑之嘌呤酮衍生物（一）
TWI423978B (zh) 作為ｈｍ７４ａ同效劑之嘌呤酮衍生物（二）
CN102695510A (zh) 囊性纤维化跨膜传导调节蛋白的嘧啶并-吡咯并-喹喔啉二酮抑制剂及其用途
JP6421185B2 (ja) ベンゾイミダゾール−プロリン誘導体の使用
BR112014027406B1 (pt) Composto, composição e uso de um composto
US20110105565A1 (en) Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
USRE48842E1 (en) Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
US8829002B2 (en) Substituted methyl amines, serotonin 5-HT6 receptor antagonists, methods for production and use thereof
CN117529474B (zh) N-取代苯基磺酰胺类化合物及其用途
WO2021078811A1 (en) Novel heterocyclic compounds
CN114656472B (zh) 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途
RU2730855C2 (ru) Кфтр регуляторы и способы их применения
KR20230002592A (ko) E형 간염의 치료를 위한 바이사이클릭 및 모노사이클릭 뉴클레오시드 유사체
WO2023090411A1 (ja) 心疾患または骨格筋の疾患の治療用医薬
CA2748982A1 (en) Thienopyridines as pharmacologically active agents
TW202207919A (zh) 脂肪性肝疾患的治療用醫藥
KR101459720B1 (ko) 세로토닌 5-ＨＴ6 저해 활성을 갖는 5-설포닐아미노-5,6-다이하이드로-1Ｈ-피라졸로[3,4-ｃ]피리딘-7(4Ｈ)-온 화합물
CN114671876B (zh) 新型茶碱类化合物、异构体或盐及其制备方法和用途
KR20210093577A (ko) 항결핵제 치료 효과 증진용 조성물
CN119823089A (zh) 一种n-苯基-2-氮杂环乙酰胺衍生物及其制备方法与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120926